July 07, 2021
Video
Dr Andrew J. Armstrong reviews the safety of LuPSMA therapy as compared to cabazitaxel as seen in the phase 2 TheraP trial and comments on sequencing strategies for patients with metastatic castration-resistant prostate cancer.
July 07, 2021
Video
An expert in prostate cancer comments on the appropriate patient population for Lutetium-177 PSMA-617 therapy for the management of metastatic castration-resistant prostate cancer.
July 07, 2021
Video
Dr Andrew J. Armstrong reviews the phase 3 VISION trial evaluating the use of LuPSMA therapy in patients with progressive PSMA-positive metastatic castrate-resistant prostate cancer.
June 30, 2021
Video
Andrew J. Armstrong, MD, MSc, discusses the survival benefit of LuPSMA therapy in patients with metastatic castration-resistant prostate cancer and evaluates the response to therapy compared with other agents.
June 30, 2021
Video
Andrew J. Armstrong, MD, MSc, provides insight on unmet needs and the use of androgen receptor inhibitors for patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.